Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review

Ocular neovascularization (NV) plays a central role in the pathogenesis of various ocular diseases including diabetic retinopathy, age-related macular degeneration, retinoblastoma, retinitis pigmentosa and may lead to loss of vision if not controlled in time. Several clinical trials elucidate the ce...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Experimental eye research Ročník 202; s. 108329
Hlavní autoři: Supe, Shibani, Upadhya, Archana, Singh, Kavita
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.01.2021
Témata:
Cationic polymer
Diabetic Retinopathy - genetics
Eye - blood supply
Genetic Therapy - methods
Humans
Liposomes
Neovascularization, Pathologic - therapy
Ocular cular siRNA delivery
Ocular neovascularization (NV)
Polyplexes, Lipoplexes, siRNA formulations, Diabetic retinopathy, Age-related macular degeneration, Patents on siRNA against ocular NV, Clinical trials
RNA Interference
RNA, Small Interfering - genetics
Small interfering RNA (siRNA)
Vascular endothelial growth factor (VEGF)
Vascular Endothelial Growth Factor A - genetics
Ocular cular siRNA delivery
Ethylene glycol
PubChem CID: 9033
PubChem CID: 24847767
Vascular endothelial growth factor (VEGF)
PubChem CID: 174
PEG2000 DSPE
Ocular neovascularization (NV)
Small interfering RNA (siRNA)
Poly-l-lysine
PubChem CID: 447078
lysine
PubChem CID: 21896651
Polyethylenimine
1, 2-distearoyl-sn-glycero-3-phosphoethanolamine
Cationic polymer
PubChem CID: 162282
PubChem CID 5962
Liposomes
Polyplexes, Lipoplexes, siRNA formulations, Diabetic retinopathy, Age-related macular degeneration, Patents on siRNA against ocular NV, Clinical trials
Chitosan
PubChem CID 406952
Hyaluronic acid
ISSN:0014-4835, 1096-0007, 1096-0007
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Ocular neovascularization (NV) plays a central role in the pathogenesis of various ocular diseases including diabetic retinopathy, age-related macular degeneration, retinoblastoma, retinitis pigmentosa and may lead to loss of vision if not controlled in time. Several clinical trials elucidate the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of the ocular neovascularization. The advent and extensive use of ocular anti-VEGF therapy heralded a new age in the treatment of retinal vascular and exudative diseases. RNA interference (RNAi) can be used to inhibit the in-vitro and in-vivo expression of specific genes and thus provides an extremely useful method for investigating gene activity with minimal toxicity. siRNA targeting VEGF overcomes many drawbacks associated with the conventional treatment available for the treatment of ocular neovascularization. However, delivery methods that protect the siRNA against degradation and are appropriate for long-term care will help increase the effectiveness of RNAi-based anti-VEGF ocular therapies. Several nanotechnology approaches have been explored by formulation scientists for delivery of siRNA to the eye; targeting particularly VEGF for the treatment of NV. This review mainly focuses on current updates in various pre-clinical and clinical siRNA strategies for targeting VEGF involved in the development of ocular neovascularization. •Ocular NV plays a central role in the pathogenesis of various ocular diseases.•Ocular NV is usually associated with loss of vision in diabetic retinopathy and age-related macular degeneration.•VEGF and its isoforms are recognized as the principal targets for the treatment of ocular NV.•siRNA strategies to downregulate VEGF are being explored.•Several nanotechnology approaches are employed for the delivery of VEGF siRNA in the treatment of ocular NV.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0014-4835
1096-0007
1096-0007
DOI:10.1016/j.exer.2020.108329